Real-Life Use Patterns of Androgen Receptor Pathway Inhibitors (ARPIs): A Nationwide Register-Based Study in Finland During 2012–2023

Tiivistelmä

Androgen pathway inhibitors (ARPIs) are widely used in prostate cancer. We conducted a register data-based analysis assessing their use and especially sequential use, e.g., use of one medicine after another, in Finland by using a dataset covering the whole country during 2012–2023. We found that one-third of patients use at least two ARPIs sequentially to inhibit testosterone effect. The total cost of sequential use was nearly €44 million. However, there are no large clinical trials published demonstrating the benefits of sequential treatment. More evidence is needed to justify sequential use.

Lue koko artikkeli (mdpi.com) 

Tekijät

Terhi Kurko, Pekka Heino, Pirkko-Liisa Kellokumpu-Lehtinen, Kati Sarnola, Hanna Koskinen, Maarit Bärlund

Lisätietoja julkaisusta

• Vertaisarvioitu: ei.
• Avoin saatavuus: kyllä.
• Koko viite: Kurko, T., Heino, P., Kellokumpu-Lehtinen, P.-L., Sarnola, K., Koskinen, H., & Bärlund, M. (2025). Real-Life Use Patterns of Androgen Receptor Pathway Inhibitors (ARPIs): A Nationwide Register-Based Study in Finland During 2012–2023. Cancers, 17(19), 3162. https://doi.org/10.3390/cancers17193162